Literature DB >> 18335327

beta(3)-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women.

Katarzyna Dunajska1, Felicja Lwow, Andrzej Milewicz, Diana Jedrzejuk, Lukasz Laczmanski, Kinga Belowska-Bien, Joanna Urban, Andrzej Szuba.   

Abstract

OBJECTIVES: Some studies indicate that the Trp64Arg polymorphism in the gene encoding the beta(3)-adrenergic receptor (ADRB3) is associated with obesity, insulin resistance and earlier onset of type 2 diabetes mellitus. The aim of the present study was to evaluate the frequency of ADRB3 polymorphism and its association with metabolic syndrome in postmenopausal women.
METHODS: We performed the study on 284 randomly chosen postmenopausal women, aged 50-60 years, who were then selected to the study. Measurements of anthropometric parameters and biochemical estimations such as lipid profile, glucose and insulin level in serum were carried out using commercial kits. ADRB3 genotyping was performed by polymerase chain reaction and mini-sequencing.
RESULTS: The frequency of the Trp64/Arg64 genotype in the investigated population was 13%, and of the Trp64/Trp64 genotype, 85%. The Arg64/Arg64 genotype was present in only 2% of women. Metabolic syndrome was recognized in 22% of women bearing Trp64/Arg64 genotype and in 14% of women bearing Trp64/Trp64 genotype, without a statistically significant difference between the two groups (p > 0.05 in the chi(2) test). Women bearing the Trp64/Arg64 genotype had lower serum levels of high-density lipoprotein cholesterol (HDL-C) than Trp64/Trp64 genotype women (63.2 +/- 13.0 vs. 71.4 +/- 17.4 mg/dl). Both groups did not differ in any other investigated parameter.
CONCLUSION: Trp64Arg polymorphism of the beta(3)-adrenergic receptor gene is not related to metabolic syndrome in postmenopausal Polish women; however, it seems to be associated with decreased HDL-C levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335327     DOI: 10.1080/09513590801921686

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

Review 1.  {beta}-Adrenoceptor gene variation and intermediate physiological traits: prediction of distant phenotype.

Authors:  John H Eisenach; Erica D Wittwer
Journal:  Exp Physiol       Date:  2010-04-09       Impact factor: 2.969

2.  Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey.

Authors:  Man-huei Chang; Ajay Yesupriya; Renée M Ned; Patricia W Mueller; Nicole F Dowling
Journal:  BMC Med Genet       Date:  2010-04-20       Impact factor: 2.103

3.  Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome.

Authors:  Kazuko Masuo
Journal:  Int J Hypertens       Date:  2010-10-21       Impact factor: 2.420

4.  Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.

Authors:  Min Yang; Qiong Huang; Jing Wu; Ji-Ye Yin; Hong Sun; Hai-Ling Liu; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

5.  ADRB3 polymorphism rs4994 (Trp64Arg) associates significantly with bodyweight elevation and dyslipidaemias in Saudis but not rs1801253 (Arg389Gly) polymorphism in ARDB1.

Authors:  Maha Daghestani; Mazin Daghestani; Mamoon Daghistani; Abdelmoneim Eldali; Zeinab K Hassan; Maha H Elamin; Arjumand Warsy
Journal:  Lipids Health Dis       Date:  2018-03-27       Impact factor: 3.876

6.  The Association of Trp64Arg Polymorphism in the Beta-Adrenergic Receptor With Insulin Resistance: Meta-Analysis.

Authors:  Hai-Dan Wang; Cai-Shun Zhang; Man-Wen Li; Qian Lin; Qing Zhang; De-Feng Liu; Zheng-Ye Ma; Jing Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-26       Impact factor: 5.555

7.  PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders.

Authors:  Bogna Grygiel-Górniak; Iwona Ziółkowska-Suchanek; Elżbieta Kaczmarek; Maria Mosor; Jerzy Nowak; Mariusz Puszczewicz
Journal:  Clin Interv Aging       Date:  2018-03-22       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.